VEGFA and age-related macular degeneration: Faricimab, a fully human 150 k Da monoclonal antibody of bispecific design, concurrently targes VEGF-A and angiopoietin 2 (Ang-2), disrupting two pivotal signaling pathways in the pathogenesis of AMD.